Source disclosure: February 13, 2026
BrightPath Biotherapeutics Co., Ltd. [4594.T]
TOKYO, Feb 19 (Pulse News Wire) – Brightpath Biotherapeutics Co., Ltd. (4594.T) reported consolidated results for Q3 FY2026 (ending March 2026).
36 billion with an equity ratio of 79.8%.
Note: Financial figures from the earnings presentation have been removed pending correction. For accurate figures, refer to the company's earnings summary (kessan tanshin) filed separately on TDNet.
AI-translated content. 🟢 Confidence: High See terms • Original filing💬 Help us improve translation quality
Notice any errors in this article? Let us know with one click.